Перейти к содержанию

Eloxx Pharmaceuticals, Inc. (ELOX) stock: revenue, earnings & dividend

Eloxx Pharmaceuticals, Inc. (ELOX, Nasdaq): revenue, earnings, dividend and balance sheet from official SEC filings.

Stock screener ELOX · Nasdaq Pharma & Biotech US-MA

Key figures

Fiscal year
2025
Revenue
0 $
Revenue growth
-100 %
Revenue growth 5y (p.a.)
–
Net income
-6 m $
Net margin
–
Operating margin
–
Earnings per share (diluted)
-5.34 $
Dividend per share
–
Payout ratio
–
Consecutive dividend years
–
Consecutive dividend raises
–
Dividend growth 5y (p.a.)
–
Total assets
5.27 m $
Equity
-11.91 m $
Equity ratio
-225.9 %
Return on equity
–
Cash
4.79 m $
Operating cash flow
-6.33 m $
Free cash flow
–
Shares outstanding
4,086,705

History

Revenue by fiscal year

2023 0 $
2024 6.36 m $
2025 0 $

Net income by fiscal year

2016 -9.85 m $
2017 -21.21 m $
2018 -47.19 m $
2019 -50.87 m $
2020 -34.58 m $
2021 -66.73 m $
2022 -36.07 m $
2023 -17.05 m $
2024 -3.14 m $
2025 -6 m $
YearRevenueNet incomeEPSDividend per shareOperating cash flow
20250 $-6 m $-5.34 $–-6.33 m $
20246.36 m $-3.14 m $-9.20 $–-4.72 m $
20230 $-17.05 m $-72.98 $–-14.34 m $
2022–-36.07 m $-16.65 $–-31.85 m $
2021–-66.73 m $-38.15 $–-35 m $
2020–-34.58 m $––-28.17 m $
2019–-50.87 m $––-39.39 m $
2018–-47.19 m $––-31.37 m $
2017–-21.21 m $––-15.94 m $
2016–-9.85 m $––-8.84 m $

Data from XBRL filings at the SEC, processed automatically, no guarantee. Not investment advice. All filings at the SEC (EDGAR)